Proteomics International Laboratories has secured a patent from the Japan Patent Office for PromarkerEndo, its diagnostic blood test for endometriosis, ensuring intellectual property (IP) protection in the country until 16 March 2041.
This patent marks a significant advancement in the early detection of endometriosis, a condition affecting one in nine women and girls.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The test addresses the urgent need for timely and precise diagnosis of this condition, aiming to enhance patient outcomes and minimise healthcare expenses.
Proteomics International is actively seeking patent protection for the PromarkerEndo technology in other key markets, with applications pending in Australia, China, Canada, Europe, Singapore, India, South Korea, and the US.
PromarkerEndo allows for the early identification of the condition in women and girls who exhibit symptoms and determine the invasive surgery need.
Endometriosis is marked by the growth of when tissue similar to the lining of the uterus grows in other parts of the body. Traditionally, confirmation of endometriosis requires a laparoscopic procedure, which may take up to an average of seven years for the diagnosis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataProteomics International managing director Dr Richard Lipscombe said: “This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.
“Japan represents one of the largest and most advanced healthcare markets in the world. Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.”
The development of the company’s diagnostics leverages its Promarker platform, which identifies protein ‘fingerprints’ in a sample.
This technology can differentiate between individuals with and without a disease utilising only a blood test, presenting an alternative to genetic testing.
In March 2025, Proteomics International launched PromarkerD, a predictive test for diabetic kidney disease (DKD), in Australia.
